The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.
Eligibility
Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
* Established atherosclerotic cardiovascular disease (ASCVD) and/or at a high risk of ASCVD
Exclusion Criteria:
* History of confirmed or suspected homozygous familial hypercholesterolemia (HoFH)
* Chronic liver disease
* Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe
Primary outcome measure(s)
Percent Change from Baseline in LDL-C — Baseline, Day 90
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.